http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PL-426916-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f13ddbf0eb3fbeb247f008d3298012de |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0455 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-227 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D219-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D219-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D219-02 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K101-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D219-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-62 |
| filingDate | 2018-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8e4563e7677d857d75c8ca2f988f798 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f8970c6bc32ab1e24cd41b88c8c97e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72cbbf1989ffcf2317c8abd99320ca93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f729ba3293f9cc3cd871dcf459723d29 |
| publicationDate | 2020-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PL-426916-A1 |
| titleOfInvention | Radiolabelled compound of a quaternary ammonium salt of a polycyclic aromatic amine, the use of a radiolabeled compound in a positron emission tomography diagnostic method, as well as a pharmaceutical composition containing a radiolabeled compound of a quaternary ammonium salt of a polycyclic aromatic amine |
| abstract | The subject of this application is a radiolabelled compound of a quaternary ammonium salt of a polycyclic aromatic amine of formula I, wherein the wavy line represents a single bond between a non-knotic carbon atom of an aromatic polycyclic system and a substituent R1 independently selected from hydrogen, halogen, hydroxyl optionally protected, C1-4alkoxy, nitro, amino optionally having 1 or 2 hydrogen atoms replaced by C1-6alkyl or having 2 hydrogen atoms replaced by C2-5alkylene to form a heterocyclic ring, a chained C1-6 carbon group optionally having a halogen, carboxyl, formyl or C1-4alkanesulfone substituent, and a phenyl group optionally having 1-5 substituents independently selected from halogens, chained C1-6 carbon substituent, halogenated C1-6 carbon chained substituent, optionally protected hydroxy, C1-4alkoxy, amino optionally having 1-2 hydrogen atoms replaced with C1-6alkyl; R2 in formula I is a chain aliphatic substituent having a -CH2- fragment as the terminal chain member to which chain is optionally attached a phenyl group optionally having 1-3 substituents selected from halogens and C1-6alkyl, and - if the chain contains at least 2 atoms carbon - in which chain between the carbon atoms there is optionally a divalent linker selected from oxygen atom -O-, sulfur atom -S- and C3-6cycloalkylene, where R2 has a total of 1-16 carbon atoms, and a hydrogen atom on one of the the carbon atoms are replaced by the 18F fluorine radioisotope; R3 and R4 occur together and represent a 1,3-butadienyl divalent substituent whose terminal carbon atoms are linked to the adjacent non-node carbon atoms of the B ring to form an aromatic C ring fused to the ring system A and B, having R1 substituents on non-node carbon atoms; n is an integer equal to 9; X- is a pharmaceutically acceptable counter-ion, which is an anion of a monobasic inorganic acid, a mono-negative anion of a polybasic inorganic acid, an alkanecarboxylic acid anion, an aliphatic sulphonic acid anion, an aromatic sulphonic acid anion, an acidic amino acid anion; and also either a hydrate or a solvate thereof. The application also relates to the use of the subject compound and a pharmaceutical composition containing the subject compound. |
| priorityDate | 2018-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.